Experimental Treatment Pushed by ALS Patients Gets Day Before FDA, But Agency Unconvinced It Works

September 25, 2023

(Associated Press) – The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by patients with the fatal neurodegenerative disease. Those advocates still face one giant hurdle: FDA regulators say the treatment hasn’t been shown to work. (Read More)